US 11,739,323 B2
Micro-RNAs as biomarkers for subconcussive and concussive injury and therapeutic applications
Matthew B. Hudson, Philadelphia, PA (US); Dianne Langford, Bala Cynwyd, PA (US); John Jeka, Philadelphia, PA (US); and Ryan Tierney, Levittown, PA (US)
Assigned to Temple University-Of The Commonwealth System of Higher Education, Philadelphia, PA (US)
Filed by Temple University—Of The Commonwealth System of Higher Education, Philadelphia, PA (US)
Filed on Jun. 7, 2018, as Appl. No. 16/1,997.
Claims priority of provisional application 62/516,760, filed on Jun. 8, 2017.
Prior Publication US 2018/0355356 A1, Dec. 13, 2018
Int. Cl. C12N 15/113 (2010.01); C12Q 1/6876 (2018.01); A61P 25/00 (2006.01); C12Q 1/6883 (2018.01)
CPC C12N 15/113 (2013.01) [A61P 25/00 (2018.01); C12Q 1/6876 (2013.01); C12Q 1/6883 (2013.01); C12N 2310/113 (2013.01); C12N 2310/141 (2013.01); C12Q 2600/178 (2013.01)] 2 Claims
 
1. A method of assessing the level of at least one micro RNA (miR) in a subject, wherein the subject has received a head impact, the method comprising:
a) obtaining exosomal RNA from a biological sample from the subject, wherein the biological sample is selected from the group consisting of blood, serum, and a combination thereof, wherein the sample is obtained 24 hours post impact,
b) contacting the sample with at least one selected from the group consisting of:
i) at least one probe that hybridizes to at least miR selected from the group consisting of miR-7844-5p, miR-144-5p, miR-221-5p, miR-22-3p, -miR-92b-5p, and miR-423-5p, and
ii) at least one primer for amplification of at least miR selected from the group consisting of miR-7844-5p, miR-144-5p, miR-221-5p, miR-22-3p, -miR-92b-5p, and miR-423-5p,
c) determining the level of at least one miR selected from the group consisting of miR-7844-5p, miR-144-5p, miR-221-5p, miR-22-3p, -miR-92b-5p, and miR-423-5p in the biological sample,
d) comparing the level of the at least one miR in the biological sample with the level of the at least one miRNA selected from the group consisting of miR-7844-5p, miR-144-5p, miR-221-5p, miR-22-3p, miR-92b-5p, and miR-423-5p in a comparator, wherein the comparator is the level of the miRNA in one or more healthy subject of reasonably matched background, and
e) identifying the subject as having a substantial change in miR levels when the level of the at least one miRNA is at least one selected from the group consisting of a decreased level of miR-7844-5p, a decreased level of miR-144-5p, a decreased level of miR-221-5p, a decreased level of miR-22-3p, an increased level of miR-92b-5p, and an increased level of miR-423-5p,
wherein the level of the at least one miRNA selected from the group consisting of miR-7844-5p, miR-144-5p, miR-221-5p, and miR-22-3p is lower than the level of the at least one miRNA in the comparator by at least three-fold;
wherein the level of the at least one miRNA selected from the group consisting of miR-92b-5p and miR-423-5p is greater than the level of the at least one miRNA in the comparator by at least three-fold.